Given that ATM/Chk2 activation profiles are the same in topotecan-sensitive and -resistant cells, ATR/Chk1 activation may dictate and distinguish DNA damage responses in cancer cells with TOP1 inhibition. This evidence concerns the gene CHEK1 and cancer.